0001022079-19-000106.txt : 20190408 0001022079-19-000106.hdr.sgml : 20190408 20190408162457 ACCESSION NUMBER: 0001022079-19-000106 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190404 FILED AS OF DATE: 20190408 DATE AS OF CHANGE: 20190408 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Doherty Catherine T. CENTRAL INDEX KEY: 0001520897 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-12215 FILM NUMBER: 19737670 MAIL ADDRESS: STREET 1: C/O QUEST DIAGNOSTICS STREET 2: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: QUEST DIAGNOSTICS INC CENTRAL INDEX KEY: 0001022079 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 161387862 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 BUSINESS PHONE: 9735202700 MAIL ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 FORMER COMPANY: FORMER CONFORMED NAME: CORNING CLINICAL LABORATORIES INC DATE OF NAME CHANGE: 19960903 4 1 wf-form4_155475508352754.xml FORM 4 X0306 4 2019-04-04 0 0001022079 QUEST DIAGNOSTICS INC DGX 0001520897 Doherty Catherine T. 500 PLAZA DRIVE SECAUCUS NJ 07094 0 1 0 0 SVP, Group Exec. Clin. Fran. Common Stock 2019-04-04 4 M 0 60492 71.17 A 133908 D Common Stock 2019-04-04 4 S 0 60492 90.593 D 73416 D Common Stock 2019-04-04 4 S 0 5890 90.592 D 67526 D Common Stock 3924 I 401(k)/SDCP Non-Qualifed Stock Option (right to buy) 71.17 2019-04-04 4 M 0 60492 71.17 D 2025-02-23 Common Stock 60492.0 0 D This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on March 6, 2019. This transaction was executed in multiple trades at prices ranging from $90.08 to $91.01. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on March 6, 2019. This transaction was executed in multiple trades at prices ranging from $90.18 to $91.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date. The options vested in three annual installments beginning with the first on February 23, 2016, the second on February 23, 2017 and the final on February 23, 2018. /s/ William J. O'Shaughnessy, Jr., Attorney in Fact for Catherine T. Doherty 2019-04-08